Topic: bone marrow stem cells
Fresh off a $55.5 million round, IFM Therapeutics snagged a new chief scientific officer. Michael Cooke, Ph.D., joins from stem cell biotech Magenta.
Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.
The week’s biotech news included a map of the human lung that could aid asthma drug development and a compound that thwarts rhinoviruses like colds.
Mount Sinai researchers showed that in male mouse models of heart attack, Cdx2 placental cells regenerated damaged tissue.
Pluristem has reached a stellar deal with NASA that will see its cell therapies tested against the health problems caused by spending time in space.
John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.
A new week, another ditched IPO as BioCardia fails to find enough interest in its regenerative heart failure candidate in a tough financial market.